Supporting Information

Nanoparticle – macrophage interactions: balance between clearance and cellular targeting

Rahul Rattan,^{a,c} Somnath Bhattacharjee,^c Hong Zong,^c Corban Swain,^{a, c} Muneeb A. Siddiqui,^{a, c} Scott H. Visovatti,^a Yogendra Kanthi,^{a, b} Sajani Desai,^{a,c} David J. Pinsky,^a and Sascha N. Goonewardena^{a,b,c,*}

*Corresponding author: sngoonew@med.umich.edu

^aDivision of Cardiovascular Medicine, Internal Medicine, University of Michigan, Ann Arbor, MI

^bAnn Arbor Veterans Affairs Health System, Ann Arbor, MI

^cMichigan Nanotechnology Institute for Medicine and Biological Sciences, and Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan 48109, United States

Address: University of Michigan Frankel Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853



Figure S1:¹H NMR of non-targeted (without FA) and targeted (FA) conjugates



Figure S2: UPLC chromatogram of G5-Alkyne-NH₂ (1), G5-Alkyne-NHAc (2), G5-Alkyne-PEG₃ (3), G5-Alkyne-PEG₇ (4), G5-Alkyne-FA-NH₂ (5), G5-Alkyne-FA-NHAc (6), G5-Alkyne-FA-PEG₃ (7) and G5-Alkyne-FA-PEG₇ (8).



Figure S3: MALDI-mass of non-targeted (without FA) and targeted (FA) conjugates.







Figure S5: Non-specific uptake of modified conjugates in KB cells. KB cells were incubated with 10 nM of the non-targeted, surface-modified dendrimer conjugates for 2 h. After incubation, the cells were harvested and AF647 was conjugated in situ using the CuAAC approach. Dendrimer uptake was then measured using flow cytometry. *P<0.05 for NT and treatments (One way Anova, Dunnett's post-hoc test). Results are representative of 3 independent experiments.